Bill Ackman was defending Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX) today, upon which he is dependent on for a high stock price to fuel his hedge fund’s involvement in the Valeant / Allergan acquisition. The deal to purchase Allergan, Inc. (NYSE:AGN) is based in large part on the price of Valeant shares. In an interview with CNBC today, Ackman also talked about Valeant in terms of its value as a “roll up” company. Ackman teaming with Valeant to pressure Allergan As previously reported in ValueWalk, Ackman approached Valeant Pharmaceuticals Intl Inc (NYSE:VRX) (TSE:VRX), a company engaged in purchasing other medical…
Ackman: Valeant A "Good" Roll Up Firm, Strategy Synergies
Mark Melin
Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.